Melanoma research

Keyphrases

Publications

volume 34, number 3, 2024

Hemali Shah, Rose Parisi, Emily Everdell, Paul Feustel, Lindy Davis
The effect of COVID-19 on early melanoma detection. Melanoma research 34 (3) (2024)
Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma. Melanoma research 34 (3) (2024)
Sri Siddharth Nekkanti, Syed Nusrath, Rajesh Jarang, Basanth Kumar Rayani, Yerramshetty Vamshi Krishna, Kalidindi Venkata Vijaya Narsimha Raju
Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity. Melanoma research 34 (3) (2024)
Marie Fabre, Anouck Lamoureux, Laurent Meunier, Quentin Samaran, Candice Lesage, Céline Girard, Aurélie Du Thanh, Lionel Moulis, Olivier Dereure
Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey. Melanoma research 34 (3) (2024)
Aymeric Hennemann, Eve Puzenat, Marion Decreuse, Fabrice Vuillier, Charlée Nardin, François Aubin
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma. Melanoma research 34 (3) (2024)
Sri Siddharth Nekkanti, Syed Nusrath, Rajesh Jarang, Basanth Kumar Rayani, Yerramshetty Vamshi Krishna, Kalidindi Venkata Vijaya Narsimha Raju
Feasibility and efficacy of indocyanine green in monitoring systemic drug leakage during isolated limb perfusion for recurrent melanoma of extremity. Melanoma research 34 (3) (2024)
Carrie-Anne Ng, Tim Luckett, Brendan Mulhern, Damien Kee, Julia Lai-Kwon, Anthony M Joshua
What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life. Melanoma research 34 (3) (2024)
Peizhou Wang, Tun Liu, Qingguo Zhang, Pan Luo
Genetic causal relationship between gut microbiota and cutaneous melanoma: a two-sample Mendelian randomization study. Melanoma research 34 (3) (2024)
Giuseppe De Pinto, Silvia Mignozzi, Carlo La Vecchia, Fabio Levi, Eva Negri, Claudia Santucci
Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma research 34 (3) (2024)

volume 34, number 4, 2024

Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel, Zachary S Morris, Jens Eickhoff, Michael A Newton, Irene M Ong, Rene Welch Schwartz, Rubi Hayim, Ilene D Kurzman, Michelle Turek, David M Vail
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma. Melanoma research 34 (4) (2024)
An-Sofie Vander Mijnsbrugge, Justine Cerckel, Iris Dirven, Jens Tijtgat, Manon Vounckx, Nele Claes, Bart Neyns
Regorafenib in patients with pretreated advanced melanoma: a single-center case series. Melanoma research 34 (4) (2024)
Lawrence W Wu, Jacqueline J Tao, Diana McDonnell, Benjamin Izar
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition. Melanoma research 34 (4) (2024)
Alice Indini, Rossana Gueli, Michele Cerati, Erika Rijavec, Marco Parravicini, Sabrina Casagrande, Cristina Rovelli, Paolo Antonio Grossi, Francesco Grossi
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma. Melanoma research 34 (4) (2024)
Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel, Zachary S Morris, Jens Eickhoff, Michael A Newton, Irene M Ong, Rene Welch Schwartz, Rubi Hayim, Ilene D Kurzman, Michelle Turek, David M Vail
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma. Melanoma research 34 (4) (2024)
Yao Gao, Yao Wang, Yueyue Luo, Yong Zhang, Saiqi Wang, Xiance Tang, Peng Qin, Benling Xu, Quanli Gao, Tiepeng Li
Pretreatment CD8 + PD-1 + to CD4 + PD-1 + ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors. Melanoma research 34 (4) (2024)
Shiwen Wang, Hongyu Zhou, Yangyang Ma, Sha Jin, Yige Zhao, Panpan Wang, Chenyu Tang, Mengyan Zhu, Jiaqi Wang, Ping Wang
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site. Melanoma research 34 (4) (2024)
Elisa Orlandi, Laura Ceccuzzi, Francesca Belpinati, Monica Rodolfo, Giovanni Malerba, Elisabetta Trabetti, Macarena Gomez-Lira, Maria Grazia Romanelli
Sex-dependent interaction of PTGS2 with miR-146a as risk factor for melanoma and the impact of sex hormones in gene expression in skin cells. Melanoma research 34 (4) (2024)
Prisca Bustamante, Jacqueline Coblentz, Christina Mastromonaco, Emma Youhnovska, Hiroaki Ito, Rita Pinto Proença, Cristina Fonseca, Kyle Dickinson, Emily Marcotte, Myriam MacDonald, Ana-Beatriz Toledo-Dias, Sabrina Bergeron, Alicia Goyeneche, Rafaella Atherino Schmidt Andujar, Thupten Tsering, Alexander Laskaris, Eva Jin, Amélie Nadeau, Tiffany Porraccio, Miguel N Burnier, Julia V Burnier
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model. Melanoma research 34 (4) (2024)
Mark R Albertini, Cindy L Zuleger, Erik A Ranheim, Oyewale Shiyanbola, Paul M Sondel, Zachary S Morris, Jens Eickhoff, Michael A Newton, Irene M Ong, Rene Welch Schwartz, Rubi Hayim, Ilene D Kurzman, Michelle Turek, David M Vail
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma. Melanoma research 34 (4) (2024)
Huasheng Liu, Hong Jiang, Qianqian Shan
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis. Melanoma research 34 (4) (2024)
Elisa Orlandi, Laura Ceccuzzi, Francesca Belpinati, Monica Rodolfo, Giovanni Malerba, Elisabetta Trabetti, Macarena Gomez-Lira, Maria Grazia Romanelli
Sex-dependent interaction of PTGS2 with miR-146a as risk factor for melanoma and the impact of sex hormones in gene expression in skin cells. Melanoma research 34 (4) (2024)
Wolfram Samlowski, Michelle A Silver, Andriana Hohlbauch, Shujing Zhang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Yunfei Wang, Ila Sruti, Ruixuan Jiang
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma. Melanoma research 34 (4) (2024)
Ahmet Anil Ozluk, Damla Gunenc, Saadet Sim Yildirim, Burcak Karaca
Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature. Melanoma research 34 (4) (2024)
Jon J Kibbie, Sophia M Zita, Robert P Dellavalle, Cory A Dunnick, Cheryl A Armstrong
The number needed to biopsy for cutaneous melanoma in academic dermatology clinics. Melanoma research 34 (4) (2024)
Yao Gao, Yao Wang, Yueyue Luo, Yong Zhang, Saiqi Wang, Xiance Tang, Peng Qin, Benling Xu, Quanli Gao, Tiepeng Li
Pretreatment CD8 + PD-1 + to CD4 + PD-1 + ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors. Melanoma research 34 (4) (2024)
Huasheng Liu, Hong Jiang, Qianqian Shan
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis. Melanoma research 34 (4) (2024)
Vincenzo Maione, Martina Perantoni, Luca Bettolini, Stefano Bighetti, Mariachiara Arisi, Cesare Tomasi, Paolo Incardona, Piergiacomo Calzavara-Pinton
Influence of regression, its extent and tumor-infiltrating lymphocytes on sentinel node status, relapse, and survival in a 10-year retrospective study of melanoma patients. Melanoma research 34 (4) (2024)
D Suwajanakorn, A M Lane, A K Go, C D Hartley, M Oxenreiter, F Wu, E S Gragoudas, R J Sullivan, K Montazeri, I K Kim
Impact of gene expression profiling on diagnosis and survival after metastasis in patients with uveal melanoma. Melanoma research 34 (4) (2024)
Lawrence W Wu, Jacqueline J Tao, Diana McDonnell, Benjamin Izar
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition. Melanoma research 34 (4) (2024)

volume 34, number 5, 2024

Claudia Fokken, Ivan Silbern, Orr Shomroni, Kuan-Ting Pan, Sergey Ryazanov, Andrei Leonov, Nadine Winkler, Henning Urlaub, Christian Griesinger, Dorothea Becker
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins. Melanoma research 34 (5) (2024)
Sanjay Chandrasekaran, You-Li Ling, Jackson Tang
Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF -mutated melanoma patients in the United States. Melanoma research 34 (5) (2024)
Camilla Mattiuzzi, Giuseppe Lippi
The death rate for melanoma remained unchanged in the USA during the coronavirus disease 2019 pandemic. Melanoma research 34 (5) (2024)
Nethanel Asher, Neta Bar-Hai, Guy Ben-Betzalel, Ronen Stoff, Shirly Grynberg, Jacob Schachter, Ronnie Frommer-Shapira
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy. Melanoma research 34 (5) (2024)
Joseph B Elmes, Jessica M Davis, Laura W Musselwhite, Zane Chiad, Donald C Moore, Asim Amin
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis. Melanoma research 34 (5) (2024)
Nethanel Asher, Neta Bar-Hai, Guy Ben-Betzalel, Ronen Stoff, Shirly Grynberg, Jacob Schachter, Ronnie Frommer-Shapira
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy. Melanoma research 34 (5) (2024)
Claudia Fokken, Ivan Silbern, Orr Shomroni, Kuan-Ting Pan, Sergey Ryazanov, Andrei Leonov, Nadine Winkler, Henning Urlaub, Christian Griesinger, Dorothea Becker
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins. Melanoma research 34 (5) (2024)
Sanjay Chandrasekaran, You-Li Ling, Jackson Tang
Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF -mutated melanoma patients in the United States. Melanoma research 34 (5) (2024)
Nilesh Kodali, Abhijit Bhattaru, Isabella Blanchard, Yash Sharma, Shari R Lipner
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis. Melanoma research 34 (5) (2024)
Federica Dini, Pietro Susini, Biancamaria Zuccaro, Giuseppe Nisi, Roberto Cuomo, Luca Grimaldi, Gabriella Perillo, Luca Tinunin, Pietro Antonini, Alessandro Innocenti, Giovanni Cecchi, Elisabetta Gambale, Laura Doni, Cinzia Mazzini, Nicola Santoro, Vincenzo De Giorgi
Head and neck melanoma: the eyelid region has a better prognosis and easier management. A retrospective survey and systematic review. Melanoma research 34 (5) (2024)
Sanjay Chandrasekaran, You-Li Ling, Jackson Tang
Real-world use and outcomes of targeted therapy and immunotherapy for adjuvant treatment of BRAF -mutated melanoma patients in the United States. Melanoma research 34 (5) (2024)
Pan Luo, Rui Guo, Dejin Gao, Qingguo Zhang
Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study. Melanoma research 34 (5) (2024)
Joseph B Elmes, Jessica M Davis, Laura W Musselwhite, Zane Chiad, Donald C Moore, Asim Amin
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis. Melanoma research 34 (5) (2024)
Sarah E Lochrin, Marina K Cugliari, Randy Yeh, Alexander N Shoushtari
Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma. Melanoma research 34 (5) (2024)
Antonios Tsimpidakis, Ioannis-Alexios Koumprentziotis, Evanthia Mastoraki, Michaella Plaka, Helen Gogas, Alexander Stratigos, Vasiliki Nikolaou
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight. Melanoma research 34 (5) (2024)
Antonios Tsimpidakis, Ioannis-Alexios Koumprentziotis, Evanthia Mastoraki, Michaella Plaka, Helen Gogas, Alexander Stratigos, Vasiliki Nikolaou
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight. Melanoma research 34 (5) (2024)
Nilesh Kodali, Abhijit Bhattaru, Isabella Blanchard, Yash Sharma, Shari R Lipner
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis. Melanoma research 34 (5) (2024)
Claudia Fokken, Ivan Silbern, Orr Shomroni, Kuan-Ting Pan, Sergey Ryazanov, Andrei Leonov, Nadine Winkler, Henning Urlaub, Christian Griesinger, Dorothea Becker
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins. Melanoma research 34 (5) (2024)
Pan Luo, Rui Guo, Dejin Gao, Qingguo Zhang
Causal relationship between sex hormones and cutaneous melanoma: a two-sample Mendelian randomized study. Melanoma research 34 (5) (2024)
Sarah E Lochrin, Marina K Cugliari, Randy Yeh, Alexander N Shoushtari
Efficacy of axitinib in a US cohort of patients with programmed cell death protein 1-resistant mucosal melanoma. Melanoma research 34 (5) (2024)
Federica Dini, Pietro Susini, Biancamaria Zuccaro, Giuseppe Nisi, Roberto Cuomo, Luca Grimaldi, Gabriella Perillo, Luca Tinunin, Pietro Antonini, Alessandro Innocenti, Giovanni Cecchi, Elisabetta Gambale, Laura Doni, Cinzia Mazzini, Nicola Santoro, Vincenzo De Giorgi
Head and neck melanoma: the eyelid region has a better prognosis and easier management. A retrospective survey and systematic review. Melanoma research 34 (5) (2024)